PLYMOUTH MEETING, Pa.& WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, and IntrinsiQ Research, the premier provider of U.S. oncology information, today announced a multi-year alliance to support the industry’s growing need for comprehensive, global insights into cancer treatments. Through the alliance, IMS gains an exclusive license to incorporate IntrinsiQ’s U.S.-based anonymized patient-level oncology information into IMS’s multi-country oncology offering--providing a complete view of cancer care into seven major markets worldwide. The integration of this information, together with IMS’s advanced analytics and global consulting capabilities, will provide the evidential database -- and expertise -- to help pharmaceutical and biotech clients make more informed decisions in this rapidly expanding, increasingly competitive space.
